SOURCE: IBC Life Sciences

June 23, 2005 08:38 ET

Forging a New Frontier in Drug/Device Combination Products

Conference Addresses Development, Regulatory and Legal Hurdles to Gain Approval

WESTBOROUGH, MA -- (MARKET WIRE) -- June 23, 2005 -- Drug/device combination products are slated to hit $9.5 billion by 2009. This rapidly expanding market provides valuable opportunities to strategically diversify market reach and maximize product portfolios. Understanding the development and regulatory pathways is the challenge. To keep pace with this market, IBC has created a platform for research and business executives to collaborate on best practices and provide innovative products.

IBC's conference on Drug/Device Combinations Products: Overcoming Development, Regulatory and Legal Hurdles to Gain Approval bring scientists and business executives together to address the growing regulatory requirements for combination products. The event is set for September 19-20, 2005, at the Hilton Minneapolis/St. Paul Hotel in Bloomington, Minnesota.

Conference highlights include:

--  First-hand experience from industry professionals on how to meet the
    challenges with development and commercialization efforts
--  New tips and strategies from Vyteris and Genetronics highlighting the
    development and commercialization of combination products
--  Exploration of potential drawbacks associated with virtual product
    labeling
--  Identification of legal challenges for 505 (b) (2) applicants and how
    to prepare for them
    
Drug/Device Combination Products is co-located IBC's Medical Devices conference to help attendees network with colleagues and gain an edge in this increasingly competitive and dynamic market. A special keynote address from Jonathan Kahan, Esq., partner at Hogan and Hartson, on "New Development and Strategies for Device and Combination Product Clearances and Approvals" will address the combined conference audience.

To receive a press pass to attend this event, contact Andrew White directly at (508) 614-1227.

About IBC Life Sciences

IBC Life Sciences is an independent organizer that is in business to provide an unbiased forum for the evaluation of current research, market trends, technological developments and applications. IBC Life Sciences is part of IBC USA Conferences, Inc., a division of T&F Informa plc (London: TFI). T&F Informa was created through the merger of Informa Group plc and Taylor & Francis Group plc in May 2004. The two companies are market leaders in providing specialist information to commercial and academic markets through conferences and trade events, as well as the publication of academic, scientific and professional books, journals and newsletters. IBC USA Conferences is headquartered in Westborough, Massachusetts.

To review the complete agenda, visit: http://www.IBCLifeSciences.com/Combo

Contact Information

  • Contact:
    Andrew White
    IBC Life Sciences
    (508) 616-5550 Ext. 227
    Email Contact